I-Win SB 50 Capsule contains Itraconazole 50 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of a variety of fungal infections. Itraconazole exerts its therapeutic effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased membrane permeability and ultimately fungal cell death. This medication is commonly prescribed for infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other systemic and superficial mycoses caused by susceptible fungi. I-Win SB 50 Capsule is administered orally and exhibits good bioavailability, with absorption enhanced when taken with food. The drug undergoes hepatic metabolism primarily via the cytochrome P450 3A4 enzyme system, necessitating caution when co-administered with other medications metabolized by this pathway due to potential drug interactions. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and elevated liver enzymes; therefore, liver function monitoring is recommended during prolonged therapy. Contraindications include hypersensitivity to itraconazole or other azole antifungals, and it should be used cautiously in patients with hepatic impairment or congestive heart failure. I-Win SB 50 Capsule should be used under medical supervision with adherence to prescribed dosage to ensure optimal efficacy and safety.